Noble Financial analyst Robert LeBoyer maintained a Buy rating on Ayala Pharmaceuticals (AYLA - Research Report) today and set a price target of $11.00. The company's shares closed yesterday at $1.40.According to TipRanks, LeBoyer is a 4-star analyst with an average return of 7.2% and a 29.93% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Ayala Pharmaceuticals, Onconova Therapeutics, and Cocrystal Pharma.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ayala Pharmaceuticals with a $11.50 average price target.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $14.93 and a one-year low of $0.70.
https://www.tipranks.com/news/blurbs/ayala-pharmaceuticals-ayla-receives-a-buy-from-noble-financial?utm_source=advfn.com&utm_medium=referral
Ayala Pharmaceuticals (NASDAQ:AYLA)
Historical Stock Chart
From May 2023 to Jun 2023 Click Here for more Ayala Pharmaceuticals Charts.
Ayala Pharmaceuticals (NASDAQ:AYLA)
Historical Stock Chart
From Jun 2022 to Jun 2023 Click Here for more Ayala Pharmaceuticals Charts.